Opinion|Videos|May 28, 2024
Hepatic Encephalopathy: Critical Insights and Closing Thoughts
In their concluding remarks, Arun Jesudian, MD; Ralph J. Riello, PharmD, BCPS, and Chas McCormick, RPh, MBA, summarize the key takeaways and highlight the persistent unmet needs in the management of hepatic encephalopathy.
Advertisement
Episodes in this series
Advertisement
Related to this article
Pharmacists navigate BCMA therapy sequencing in relapsed/refractory multiple myeloma, weighing linvoseltamab logistics, community readiness, safety monitoring, and smoother care transitions.
The provider-administered IL-23 inhibitor improved ACR20 response vs placebo after 2 doses in the phase 3 INSPIRE-1 and INSPIRE-2 trials.
Persistent symptoms can complicate life after a multiple myeloma treatment response, making routine symptom assessment and targeted supportive care essential.
Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.
Convenience should not replace connection.
Treated patients also had fewer post-acute hospitalizations and deaths, but individuals without risk factors saw no benefit.
A pharmacy technician reflects on 3 patient encounters that reshaped his
understanding of what a real patient requires.
In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg per day was linked to more kidney failure and higher all-cause mortality.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Community Pharmacists Guide Patients New to Glucose Monitoring
2
FDA Approves Tildrakizumab for Adults With Psoriatic Arthritis
3
Long-Term Care Pharmacies Can Close the Flu Vaccination Gap Among Older Adults
4
Narrow Therapeutic Index Chemotherapy Dosing With eGFR: Safeguards for Oncology Pharmacists
5